Wednesday, March 01, 2017
Tuesday, February 28, 2017
Vitamins Gone Gummy, or Dummy?
I think this piece really does the public a disservice. Gummy vitamins are added sugar, plain and simple. The fact that people need mask supplements in candy is diametrically opposed to what supplements represent. Here are a few other things the reporters may not have thought of when stating that gummies make us more apt to take our vitamins.
There are only a few gummy products that contain natural, non-caloric sweeteners such as inulin, lo han, and stevia. Unfortunately, most people do not care for the taste, which is why there are so few of them on the market.
In our honest opinion, we would rather our clients take no supplements at all than consume sugar sweetened or artificially sweetened gummy vitamins.
- Consistently consuming candy, whether or not they contain vitamins, feeds the brain's addiction to sugar. Allowing the brain to get that fix every day only increases the desire for more products with added sugar.
- The sweeteners in gummy vitamins can reduce the effectiveness of the vitamins and minerals in the product. Sweeteners alter gut microbia in a negative way because they suppress beneficial bacteria. Beneficial gut microbes help the vitamins and minerals be absorbed. Pathogenic gut microbes do not.
- Artificial sweeteners in gummy vitamins are even worse. They still activate the brain's sugar receptors. In addition, they are chemicals which the body has to deal with excreting, instead of dealing with absorbing the vitamins and minerals.
- Most gummy vitamins are loaded with artificial fillers.
There are only a few gummy products that contain natural, non-caloric sweeteners such as inulin, lo han, and stevia. Unfortunately, most people do not care for the taste, which is why there are so few of them on the market.
In our honest opinion, we would rather our clients take no supplements at all than consume sugar sweetened or artificially sweetened gummy vitamins.
Monday, February 27, 2017
Friday, February 24, 2017
Thursday, February 23, 2017
Wednesday, February 22, 2017
Tuesday, February 21, 2017
Friday, February 17, 2017
Thursday, February 16, 2017
Wednesday, February 15, 2017
Tuesday, February 14, 2017
Friday, February 10, 2017
Thursday, February 09, 2017
Thursday, February 02, 2017
Tuesday, January 31, 2017
Monday, January 30, 2017
Wednesday, January 25, 2017
Tuesday, January 24, 2017
Monday, January 23, 2017
Friday, January 20, 2017
Thursday, January 19, 2017
Tuesday, January 17, 2017
Why the ‘gluten-free movement’ is less of a fad than we thought
https://www.washingtonpost.com/news/wonk/wp/2017/01/13/why-the-gluten-free-movement-is-less-of-a-fad-than-we-thought/?utm_term=.8033855e228b
Totally disagree with writer's statement about gluten intolerance: "In the absence of diagnostic clarity, most people who suspect they have a non-celiac gluten sensitivity confirm the finding with an inexact test. They eliminate gluten from their diet and see if their symptoms improve after that."
She is only partially right: removing gluten is the gold standard for knowing if you react. The problem is that many people remove it and never reintroduce it. To truly know if gluten is the issue, you must remove it for a period of six months, and then reintroduce it. If you get symptoms again, then you have a gluten issue, period.
Totally disagree with writer's statement about gluten intolerance: "In the absence of diagnostic clarity, most people who suspect they have a non-celiac gluten sensitivity confirm the finding with an inexact test. They eliminate gluten from their diet and see if their symptoms improve after that."
She is only partially right: removing gluten is the gold standard for knowing if you react. The problem is that many people remove it and never reintroduce it. To truly know if gluten is the issue, you must remove it for a period of six months, and then reintroduce it. If you get symptoms again, then you have a gluten issue, period.
Friday, January 13, 2017
Thursday, January 12, 2017
Tuesday, January 10, 2017
Monday, January 09, 2017
Friday, January 06, 2017
Thursday, January 05, 2017
Wednesday, January 04, 2017
Monday, January 02, 2017
Wednesday, December 21, 2016
Friday, December 16, 2016
Tuesday, December 13, 2016
Friday, December 09, 2016
Thursday, December 08, 2016
Using Adverse Event Reports to Monitor Cosmetic Safety
Center for Food Safety and Applied Nutrition
Using Adverse Event Reports to Monitor Cosmetic Safety
December 8, 2016
It’s not an exaggeration to say that everyone uses cosmetics, be it shampoo, mouthwash, a moisturizer or deodorant. The FDA monitors cosmetics on the market to ensure that they are safe for consumers.
One way in which FDA finds out about a safety issue is when an adverse event report (AER) is filed by a consumer, manufacturer, or health care professional. An adverse event could be any problem experienced when using a cosmetic product. On Tuesday, Dec. 6, 2016, FDA announced that it is making public certain data that the agency’s Center for Food Safety and Applied Nutrition (CFSAN) receives about adverse events associated with the use of its regulated products, which include cosmetics.
Why FDA Is Making Data Extracted from Reports of Adverse Events for Foods and Cosmetics Available to the Public
Using Adverse Event Reports to Monitor Cosmetic Safety
December 8, 2016
It’s not an exaggeration to say that everyone uses cosmetics, be it shampoo, mouthwash, a moisturizer or deodorant. The FDA monitors cosmetics on the market to ensure that they are safe for consumers.
One way in which FDA finds out about a safety issue is when an adverse event report (AER) is filed by a consumer, manufacturer, or health care professional. An adverse event could be any problem experienced when using a cosmetic product. On Tuesday, Dec. 6, 2016, FDA announced that it is making public certain data that the agency’s Center for Food Safety and Applied Nutrition (CFSAN) receives about adverse events associated with the use of its regulated products, which include cosmetics.
Why FDA Is Making Data Extracted from Reports of Adverse Events for Foods and Cosmetics Available to the Public
Tuesday, December 06, 2016
Monday, December 05, 2016
Thursday, December 01, 2016
Wednesday, November 30, 2016
Tuesday, November 22, 2016
Monday, November 21, 2016
Friday, November 18, 2016
Monday, November 14, 2016
Friday, November 11, 2016
Thursday, November 10, 2016
Vitamin D Eases Depression, Fatigue in Spinal Cord Patients
For patients with spinal cord injury who have insufficient levels of vitamin D, supplements can improve symptoms of depression and fatigue, according to a report presented to the American Academy of Physical Medicine and Rehabilitation 2016 Annual Assembly.
And in these patients, pain severity scores were significantly better with high-dose supplements than with low-dose supplements.
"We need to screen everyone with spinal cord injury for vitamin D," said the lead author.
In the study, all patients had levels of 25-hydroxyvitamin D were below 30, even those that hailed from "sunny California".
Patients randomly allocated to the low-dose group received 800 IU of vitamin D daily for 6 months. Those randomly assigned to the high-dose group received 2000 IU daily for 6 months if their baseline blood levels were 20 to 30. They received 4000 IU daily for 1 month and 2000 IU daily for 5 months if their baseline blood levels were lower than 20.
During the study period, all patients experienced a significant increase in average 25-hydroxyvitamin D levels. High-dose supplementation was associated with a significant decrease in depression and fatigue.
And in these patients, pain severity scores were significantly better with high-dose supplements than with low-dose supplements.
"We need to screen everyone with spinal cord injury for vitamin D," said the lead author.
In the study, all patients had levels of 25-hydroxyvitamin D were below 30, even those that hailed from "sunny California".
Patients randomly allocated to the low-dose group received 800 IU of vitamin D daily for 6 months. Those randomly assigned to the high-dose group received 2000 IU daily for 6 months if their baseline blood levels were 20 to 30. They received 4000 IU daily for 1 month and 2000 IU daily for 5 months if their baseline blood levels were lower than 20.
During the study period, all patients experienced a significant increase in average 25-hydroxyvitamin D levels. High-dose supplementation was associated with a significant decrease in depression and fatigue.
Thursday, November 03, 2016
Wednesday, November 02, 2016
Tuesday, October 25, 2016
Friday, October 21, 2016
Wednesday, October 19, 2016
Monday, October 17, 2016
Friday, October 14, 2016
Thursday, October 13, 2016
Tuesday, October 11, 2016
Why Stop at Sugary Drinks?
Tax sugary drinks to fight obesity and diabetes, World Health Organization says.
http://www.reuters.com/article/us-health-sugar-idUSKCN12B0ZB
Coke and Pepsi Give Millions to Public Health, Then Lobby Against It.
http://www.nytimes.com/2016/10/10/well/eat/coke-and-pepsi-give-millions-to-public-health-then-lobby-against-it.html?_r=0
http://www.reuters.com/article/us-health-sugar-idUSKCN12B0ZB
Coke and Pepsi Give Millions to Public Health, Then Lobby Against It.
http://www.nytimes.com/2016/10/10/well/eat/coke-and-pepsi-give-millions-to-public-health-then-lobby-against-it.html?_r=0
Friday, October 07, 2016
Tuesday, October 04, 2016
Thursday, September 29, 2016
Tuesday, September 27, 2016
Monsanto Bought Out
Monsanto has accepted Bayer AG’s $66 billion takeover offer, which will make the new entity the largest seed and pesticide company in the world.
If the merger goes through, we’ll be left with just four companies providing 59 percent of the global seeds and 64 percent of the world’s pesticides, which some predict will be a disaster for the global food system.
If the merger goes through, we’ll be left with just four companies providing 59 percent of the global seeds and 64 percent of the world’s pesticides, which some predict will be a disaster for the global food system.
Thursday, September 22, 2016
Wednesday, September 21, 2016
How Top Restaurants Rate on Reducing Use of Antibiotics in Their Meat Supply
Not surprisingly, Panera and Chipotle were rated the best.
http://webiva-downton.s3.amazonaws.com/877/c1/e/9136/1/NRDC_ChainReaction2_ExecSumm.pdf
http://webiva-downton.s3.amazonaws.com/877/c1/e/9136/1/NRDC_ChainReaction2_ExecSumm.pdf
Monday, September 19, 2016
Friday, September 16, 2016
Splenda Naturals: Here We Go!
Due to declining sales of their flagship artificial sweetener, Splenda has produced a rival to Truvia and PureVia.
It has the same ingredients as the other two: stevia extract and erythritol.
They market it as a natural non-caloric sweetener, but as you know now, erythritol is anything but natural.
https://www.splenda.com/naturals
Don't buy into the hype!
It has the same ingredients as the other two: stevia extract and erythritol.
They market it as a natural non-caloric sweetener, but as you know now, erythritol is anything but natural.
https://www.splenda.com/naturals
Don't buy into the hype!
Thursday, September 15, 2016
Huge Lancet Review on Statins Littered With Conflict of Interest
There was a ton of press on statins a few weeks ago. Take any of it with a grain of salt. Look at the conflict of interest with the authors of the study!
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)31357-5/fulltext
"Declaration of interests from the authors
JA, CB, LB, RC, JE, RP, DP, and CR work in the Clinical Trial Service Unit & Epidemiological Studies Unit (CTSU) at the University of Oxford. The CTSU has received research grants from Abbott, AstraZeneca, Bayer, GlaxoSmithKline, Merck, Novartis, Pfizer, Roche, Schering, and Solvay that are governed by University of Oxford contracts that protect its independence, and it has a staff policy of not taking personal payments from industry (with reimbursement sought only for the costs of travel and accommodation to attend scientific meetings). RC is co-inventor of a genetic test for statin-related myopathy risk, but receives no income from it. DP has participated in advisory meetings for Sanofi related to PCSK9 inhibitor therapy in his previous employment. The CTT Collaboration, which is coordinated by CTSU with colleagues from the University of Sydney, does not receive industry funding. JD has received research grants from, and served as a consultant to, Merck and Pfizer. GDS has twice received travel and accommodation funding and honoraria from Merck; DD receives compensation for serving on data monitoring committees for clinical trials (including of statins) funded by Abbvie, Actelion, Amgen, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Merck, Sanofi, and Teva. NW and ML are inventors of a combination formulation for the prevention of cardiovascular disease that includes a statin, covered by patents licensed to Polypill in which they both hold shares and which owns the website polypill.com. SMac has received research grants for research on statins and polypill development from Bristol-Myers Squibb and BUPA. SMar is co-inventor on a pending patent for a LDL cholesterol estimation method, and has served as an advisor to Sanofi, Regeneron, Quest Diagnostics, Pressed Juicery, and Abbott Nutrition. NP has received research grants and honoraria for participating in advisory meetings and giving lectures from Amgen, Lilly, Menorini, and Merck. PR has received investigator-initiated research grants from Amgen, AstraZeneca, Kowa, Novartis, and Pfizer. PSe has received research grants and honoraria for consultancies from Amgen and Pfizer. LS has undertaken advisory work unrelated to statins for AstraZeneca and GlaxoSmithKline. SY has received a research grant from AstraZeneca through Hamilton Health Sciences. AR declares that George Health Enterprises, the social enterprise arm of The George Institute, has received investment to develop combination products containing statin, aspirin, and blood-pressure-lowering drugs. JS has received grants from the National Health and Medical Research Council, Australia; Bayer Pharmaceuticals; Roche; and Merck Serono. RB, SE, BN, IR, and PSa declare no competing interests."
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)31357-5/fulltext
"Declaration of interests from the authors
JA, CB, LB, RC, JE, RP, DP, and CR work in the Clinical Trial Service Unit & Epidemiological Studies Unit (CTSU) at the University of Oxford. The CTSU has received research grants from Abbott, AstraZeneca, Bayer, GlaxoSmithKline, Merck, Novartis, Pfizer, Roche, Schering, and Solvay that are governed by University of Oxford contracts that protect its independence, and it has a staff policy of not taking personal payments from industry (with reimbursement sought only for the costs of travel and accommodation to attend scientific meetings). RC is co-inventor of a genetic test for statin-related myopathy risk, but receives no income from it. DP has participated in advisory meetings for Sanofi related to PCSK9 inhibitor therapy in his previous employment. The CTT Collaboration, which is coordinated by CTSU with colleagues from the University of Sydney, does not receive industry funding. JD has received research grants from, and served as a consultant to, Merck and Pfizer. GDS has twice received travel and accommodation funding and honoraria from Merck; DD receives compensation for serving on data monitoring committees for clinical trials (including of statins) funded by Abbvie, Actelion, Amgen, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Merck, Sanofi, and Teva. NW and ML are inventors of a combination formulation for the prevention of cardiovascular disease that includes a statin, covered by patents licensed to Polypill in which they both hold shares and which owns the website polypill.com. SMac has received research grants for research on statins and polypill development from Bristol-Myers Squibb and BUPA. SMar is co-inventor on a pending patent for a LDL cholesterol estimation method, and has served as an advisor to Sanofi, Regeneron, Quest Diagnostics, Pressed Juicery, and Abbott Nutrition. NP has received research grants and honoraria for participating in advisory meetings and giving lectures from Amgen, Lilly, Menorini, and Merck. PR has received investigator-initiated research grants from Amgen, AstraZeneca, Kowa, Novartis, and Pfizer. PSe has received research grants and honoraria for consultancies from Amgen and Pfizer. LS has undertaken advisory work unrelated to statins for AstraZeneca and GlaxoSmithKline. SY has received a research grant from AstraZeneca through Hamilton Health Sciences. AR declares that George Health Enterprises, the social enterprise arm of The George Institute, has received investment to develop combination products containing statin, aspirin, and blood-pressure-lowering drugs. JS has received grants from the National Health and Medical Research Council, Australia; Bayer Pharmaceuticals; Roche; and Merck Serono. RB, SE, BN, IR, and PSa declare no competing interests."
Yucky Federal GMO Bill Becomes Law
Aside from overriding state and local laws, what are some of the DARK Act’s other fundamental deficiencies?
- There is no requirement for on-package labeling of GMO foods.
- As many as 100 million Americans lack the ability to find out product specifics by not being able to access QR codes.
- The biotech-friendly USDA – not the FDA – is charged with creating the law’s actual labeling rules over the next two years.
- The bill leaves totally unclear what will be considered a GMO food and/or ingredient. According to the FDA, most foods typically thought of as being produced or made with GMO ingredients will not be covered by the bill’s narrow definition of genetic engineering. The USDA might raise the threshold for incidental GMO contamination from the currently accepted .09% to as high as 30% while still calling that non-GMO!
- The bill suggests that the USDA harmonize its ultimate definition of genetic engineering with the organic law’s definitions – something that could create a huge loophole into organic’s current strict prohibitions on GMO technology.
Wednesday, September 14, 2016
Monday, September 05, 2016
Friday, September 02, 2016
Subscribe to:
Posts (Atom)
